Matchpoint Therapeutics Raises $100M in Series A and Seed Funding


Matchpoint Therapeutics, a Cambridge, MA-based biotechnology corporate, raised $100M in Sequence A and Seed investment.

The $70M Sequence A spherical used to be led through Sanofi Ventures with participation from Atlas Challenge, Get right of entry to Biotechnology, Vertex Ventures HC, Digitalis Ventures, and Alexandria Challenge Investments.
The $30M Seed spherical used to be co-led through Atlas Challenge and Get right of entry to Biotechnology.

The corporate intends to make use of the budget for additional development of its proprietary platform and its discovery pipeline of novel covalent molecules, to start with enthusiastic about immunology.

Based through Drs. Grey, Chouchani, Dr. Jianwei Che, Andre Turenne (CEO) and Dr. Tinghu Zhang, Matchpoint is a biotechnology corporate harnessing covalency to find covalent drugs for the remedy of immune sicknesses and different critical sicknesses. Its proprietary Complicated Covalent Exploration (ACE) platform integrates chemoproteomics, gadget finding out and covalent chemistry library evolution.

The platform brings in combination a collection of proprietary equipment to revolutionize the invention and construction of covalent drugs:

  • chemoproteomics that identifies novel covalent binders to disease-causing proteins, together with the ones with low abundance, of their local cell surroundings and offers proteome-wide review of selectivity
  • Device finding out algorithms that expose the principles of covalency to steer goal prioritization and are expecting privileged scaffolds to improve medicinal chemistry and library design
  • Proprietary libraries of covalent compounds which can be steadily evolving and knowledgeable through predictive algorithms



Leave a Comment